# TachoSil Versus Standard Surgical Treatment for Air Leakage in Pulmonary Lobectomy (TC-021-IM)

> **NCT00293514** · PHASE3 · COMPLETED · sponsor: **Nycomed**

## Conditions studied

- Pulmonary Diseases
- Intraoperative Complications

## Interventions

- **DRUG:** Fibrinogen (human) + thrombin (human) (TachoSil)

## Key facts

- **NCT ID:** NCT00293514
- **Lead sponsor:** Nycomed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** — (—)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293514, "TachoSil Versus Standard Surgical Treatment for Air Leakage in Pulmonary Lobectomy (TC-021-IM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00293514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*